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there	 different	 degrees	 of	 formality	 in	 QRM	 -	 is	 it	 a	 spectrum,	 or	 is	 it	 a	 binary	 concept?	 	 These	
questions	 are	 explored	 in	 this	 paper.	 	 Since	 the	 introduction	 of	 ICH	Q9	 in	 2005,	 there	 have	 been	
discussions	 in	 the	 pharmaceutical	 industry	 and	 between	 regulators	 regarding	 the	 concept	 of	
formality	 in	QRM.	 	 ICH	Q9	presents	 two	principles	of	Quality	Risk	Management,	 and	one	of	 those	
refers	to	formality	–	it	states	that	“the	level	of	effort,	formality	and	documentation	of	the	quality	risk	






of	 formality	 in	 QRM,	 with	 a	 view	 to	 achieving	 a	 shared	 understanding	 as	 to	 what	 it	 means	 at	 a	
practical	level.		It	was	of	interest	that	there	was	strong	support	expressed	among	industry	and	GMP	
inspectors	for	the	use	of	less	formal	approaches	to	QRM.		The	primary	outcome	of	that	work	is	a	set	
of	 suggested	 definitions	 for	 formal	 and	 less	 formal	 approaches	 to	 QRM.	 	 There	 are	 several	
anticipated	benefits	 to	 this	work	–	 including	 that	 a	better	understanding	of	 formality	may	 lead	 to	
resources	 for	 QRM	 being	 used	 more	 efficiently	 –	 where	 lower	 risk	 issues	 are	 dealt	 with	 via	 less	
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because	 the	 guideline	 that	 has	 served	 as	 the	basis	 for	most	 risk-based	 approaches	 in	 the	
pharmaceutical	industry	for	the	past	15	years,	ICH	Q9	(1),	places	formality	(alongside	other	
concepts)	 firmly	 at	 the	 centre	 of	 QRM.	 	 ICH	 Q9	 indicates	 that,	 although	 ‘a	 systematic	
approach	to	quality	risk	management	is	generally	preferred,	it	is	neither	always	appropriate	










With	 regard	 to	 the	 reference	 to	 formality	 in	 the	 second	 principle,	 it	 is	 useful	 to	 consider	





our	work	 in	 this	area	and	 to	put	 forward	 suggested	definitions	 for	 formal	and	 less	 formal	
approaches	to	QRM,	in	an	effort	to	bring	clarity	to	this	concept.		A	greater	understanding	of	
formality	in	QRM	has	the	potential	to	lead	to	more	fit-for-purpose	applications	of	QRM,	the	














The	use	of	 formalised	Quality	Risk	Management	 (QRM)	approaches	 in	 the	pharmaceutical	





As	 noted	 above,	 the	 concept	 of	 formality	 is	 embedded	 in	 one	 of	 the	 two	 core	 ICH	 Q9	
principles	 of	 QRM.	 	 Apart	 from	 that,	 the	 guideline	 makes	 several	 other	 references	 to	
formality	in	QRM	too.		In	its	introductory	section,	for	example,	it	states:	“It	is	neither	always	
appropriate	nor	always	necessary	to	use	a	formal	risk	assessment	process	(using	recognised	
tools	 and/or	 internal	 procedures,	 e.g.	 SOPs).	 	 The	 use	 of	 informal	 risk	 management	
processes	 (using	 empirical	 tools	 and/or	 internal	 procedures)	 can	 also	 be	 considered	
acceptable.”	(1)		This	statement	indicates	that	the	use	of	empirical	tools	constitutes	informal	








have	 been	 assessed	 in	 a	 variety	 of	 informal	ways	 (empirical	 and/or	 internal	 procedures)	
based	 on,	 e.g.,	 compilation	 of	 observations,	 trends	 and	 other	 information”	 and	 that	 such	
approaches	 “continue	 to	 provide	 useful	 information	 that	 might	 support	 topics	 such	 as	
handling	of	complaints,	quality	defects,	deviations	and	allocation	of	resources.”		(1)	It	goes	
on	 to	 state	 that,	 additionally,	 “the	pharmaceutical	 industry	and	 regulators	 can	assess	and	
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and/or	 perform	 Quality	 Risk	 Management-related	 activities.	 	 These	 include	 Preliminary	
Hazard	Analysis	 (PHA),	Hazard	and	Operability	 Studies	 (HAZOP),	 Fault	 Tree	Analysis	 (FTA),	




the	Probabilistic	Risk	Assessment	 techniques	 that	 are	often	used	by	nuclear	power	plants	




and	HACCP	 (Hazard	Analysis	and	Critical	Control	Points),	which,	at	best,	provide	 for	 semi-
quantitative	 risk	 ratings,	although	one	could	argue	 that	 those	particular	 tools	are	perhaps	
more	 qualitative	 than	 quantitative,	 even	 when	 they	 generate	 numerical	 expressions	 of	
relative	risk	in	the	form	of	Risk	Priority	Numbers	(RPNs),	(8)		The	reason	for	this	is	that	RPN	
numbers	 are	 usually	 arrived	 at	 via	 the	 multiplication	 of	 what	 are	 called	 ordinal	 scale	
numbers.		These	are	numbers	that	indicate	relative	positions	on	a	scale	(e.g.	on	a	probability	
scale	 of	 1	 to	 5,	 4	 is	 higher	 than	 2,	 but	 it	may	 not	 represent	 double	 the	 probability	 of	 an	











The	 section	 in	 ICH	 Q9	 titled	 ‘Risk	Management	Methodology’	 states	 that	 the	 “degree	 of	
4




















The	 WHO	 guideline	 also	 requires	 critical	 issues	 to	 be	 addressed	 “with	 appropriate	 high	
urgency	 and	 formality”.	 	 In	 the	 section	 on	 Risk	 Communication	 and	 Documentation,	 the	
guideline	indicates	that	it	is	not	necessary	to	issue	“a	full	report	for	every	risk	assessment”,	
and	 that	 “the	 level	 of	 effort,	 formality	 and	 documentation	 of	 the	 QRM	 process	 can	 be	
commensurate	 with	 the	 level	 of	 risk”.	 	 It	 goes	 on	 to	 state	 that	 an	 organization	 “can	 be	
pragmatic	regarding	the	degree	of	formality	that	is	required;	however,	appropriate	evidence	




It	 is	 interesting	 that,	 despite	 its	 highly	 structured	 approach	 to	 risk	management,	 the	 ISO	
standard	on	the	use	of	risk	management	in	relation	to	medical	devices,	ISO	14971:2019	(13),	
makes	 only	 two	 brief	 references	 to	 formality	 –	 one	 is	 in	 a	 note	 about	 records,	 which	
indicates	that	records	serve	as	a	means	to	formalize	traceability.		The	second	relates	to	risk	
management	plans,	which	are	required	by	the	standard	to	describe	the	“activities	related	to	
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The	 International	 Standard	 ISO	 31000:2009,	 titled	 Risk	 Management	 –	 Principles	 and	
Guidelines	 (14),	 also	 refers	 to	 formality.	 	 Its	 Introduction	 section	 indicates	 that	 “when	 a	
formal	process	is	in	place	within	an	organization	for	particular	types	of	risk	or	circumstances,	














the	benefits	 that	 increased	 clarity	 for	 this	 concept	may	bring.	 	 There	 are	 several	 benefits	
that	can	reasonably	be	anticipated:		
	
• Clarity	 around	 formality	 in	 QRM	 can	 help	 ensure	 that	 the	 extent	 of	 scientific	 and	
methodological	 rigour	 that	 is	 applied	during	QRM	activities	 is	 commensurate	with	 the	
level	of	risk.	
	
• Business	 resources	 for	QRM	 can	 be	more	 efficiently	 allocated	 in	 accordance	with	 the	
level	of	potential	 risk	 that	needs	 to	be	managed	–	 lower	 risk	 issues	 can	be	dealt	with	




selecting	 the	 most	 appropriate	 tool	 for	 a	 given	 QRM	 activity	 –where	 an	 increased	
6















Dublin,	 Ireland,	 the	 Pharmaceutical	 Regulatory	 Science	 Team	 (PSRT)	 at	 the	 Technological	
University,	Dublin,	McGee	Pharma	International	and	the	Irish	Chapter	of	the	Parenteral	Drug	
Association	 (PDA),	 two	 workshops	 were	 run	 with	 representatives	 from	 pharmaceutical	
manufacturing	 companies	 in	 Ireland	 to	 explore	 the	 meaning	 and	 practical	 application	 of	
formality	in	QRM	activities.			
	
A	 total	 of	 80	 staff	 from	 50	 pharmaceutical	 companies	 attended	 the	 workshops;	 these	
included	 staff	 from	 several	 large	 biotech	manufacturing	 sites,	 as	 well	 as	 staff	 from	 small	
molecule	 API	 sites,	 non-sterile	 and	 sterile	 finished	 non-biological	 product	 sites,	 amongst	
others.			
	
The	 first	 workshop	 (November	 2016)	 focused	 on	 a	 number	 of	 key	 questions	 and	 issues,	
including:	







• Can	 a	 company	 use	 informal	 risk	 assessments	 to	 comply	 with	 EU	 GMP	 Annex	 15	
requirement	 that,	 the	 way	 in	 which	 “risk	 assessments	 are	 used	 to	 support	 validation	
7
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Overall,	 it	 was	 evident	 from	 the	 workshops	 that	 there	 was	 significant	 uncertainty	 about	
what	constituted	formality	in	the	context	of	QRM.	There	was	a	lack	of	clarity	on	what	tools,	
if	 any,	 should	be	 considered	 less	 formal	 compared	 to	other	 tools	 and	approaches,	 and	 in	
what	 situations	 they	 might	 be	 applied.	 	 While	 a	 set	 of	 keywords	 was	 developed	 which	
illustrated	to	some	extent	what	might	be	meant	by	formal	QRM	and	informal	QRM,	it	was	
8







It	was	 agreed	 that	 the	 topic	 of	 formality	 in	QRM	was	 of	 direct	 relevance	 and	 interest	 to	
medicines	manufacturers,	and	that	clearer	regulatory	guidance	in	this	area	was	needed.				
	








group	 of	 QRM	 practitioners	 formed	 a	 working	 group	 to	 further	 explore	 the	 concept	 of	









showing	 how	 a	 better	 understanding	 of	 formality	 in	 QRM	might	 help	 to	 deliver	more	
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6.	 Survey	 with	 GMP	 Inspectors	 on	 the	 Concept	 of	 Formality	 in	 QRM,	
September	2018	
	
After	 the	 working	 group	 had	 distilled	 and	 documented	 its	 thinking	 on	 what	 constituted	
formality	 in	 QRM,	 a	 survey	 was	 carried	 out	 with	 GMP	 inspectors	 during	 a	 PIC/S	 QRM	
meeting	held	 in	Taiwan	 in	September	2018.	 	 This	explored	 their	understanding	and	views	
about	the	concept	of	formality	in	QRM.				
A	 total	 of	 27	 GMP	 Inspectors	 from	 14	 different	 countries	 completed	 the	 survey.	 	 The	
countries	 in	 question	were:	Austria,	 Indonesia,	 Iran,	 Ireland,	 Italy,	Malaysia,	 Saudi	Arabia,	






• Only	22%	 indicated	 that	 they	had	a	good	understanding	of	 the	 concepts	of	 formal	
QRM	and	informal	QRM;	a	higher	number	(30%)	indicated	either	little	understanding	











• The	 inspectors	 were	 asked	 if	 there	 was	 a	 need	 for	 additional	 guidance	 for	 GMP	
inspectors	 (and	 for	 the	 industry)	 on	 what	 is	 meant	 by	 formal	 QRM	 and	 informal	
QRM.	 	 Of	 the	 25	 respondents	 who	 answered	 this	 question,	 76%	 stated	 that	
additional	 guidance	 was	 required.	 	 12%	 stated	 that	 additional	 guidance	 was	 not	
required	and	12%	said	they	didn’t	know.	
	
Overall,	 the	 survey	 results	 indicated	 that,	while	 there	was	 clear	 support	 among	 the	GMP	
inspectors	for	the	use	of	different	 levels	of	formality	 in	quality	risk	management	activities,	
there	was	also	a	need	 for	clarity	and	guidance	on	what	 is	meant	by	 formal	QRM	and	 less	
















topic.	 	 The	 definitions	 for	 Formal	QRM	and	 Lower	 Levels	 of	 Formal	QRM	were	 arrived	 at	
following	a	review	of	the	work	completed	and	the	learnings	made	up	to	that	point,	as	well	
as	the	use	of	a	structured	approach	involving	a	What,	When	and	How	methodology.		When	
developing	 the	definitions,	 various	elements	were	considered,	 including	QRM	procedures,	
risk	 assessment	 and	 QRM	 tool	 selection,	 training	 considerations,	 documentation	
requirements,	issues	associated	with	level	of	effort,	and	of	course	the	guidance	available	in	


















• Elements	 of	 the	QRM	process	 (e.g.	 Risk	Assessment)	 are	 embedded	 /	 integrated	 into	 other	







QRM	 process.	 This	 means	 that	 such	 tools	 do	 not	 have	 to	 be	 used	 in	 order	 to	 arrive	 at	
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The	 definitions	 presented	 here	 are	 also	 supported	 by	 the	 contents	 of	 the	 2010	 WHO	
guideline	 on	 QRM	 (12),	 as	 well	 as	 the	 ISO	 standard	 on	 the	 use	 of	 risk	 management	 in	
relation	 to	medical	 devices,	 ISO	 14971:2019	 (13),	 and	 the	more	 generic	 standard	 on	 Risk	
Management,	ISO	31000:2009	(14).		For	example:	
	
• In	 the	 WHO	 guideline	 on	 QRM,	 it	 is	 stated	 that	 an	 organization	 can	 be	 pragmatic	




• The	 ISO	 standard	 on	 risk	 management	 for	 medical	 devices	 requires	 a	 formal	 and	
appropriate	 way	 to	 feedback	 information	 into	 the	 risk	 management	 process.	 	 This	 is	










QRM	characteristics	 	 	 Formal	QRM	 Lower	Levels	of	Formality		
All	 four	 elements	 of	 QRM	 as	 per	 ICH	 Q9	 are	
applied	
Yes	 One	 or	 more	 of	 the	 four	
elements	may	be	present	
Stand-alone	QRM	reports	are	generated	 Yes	 Not	required,	but	outcomes	



















pertaining	 to	 formality	 in	 QRM	 (and	 other	 issues)	 had	 been	 initiated.	 	 The	 EMA	 and	 the	
European	Commission	had	initiated	work	with	ICH	to	trigger	a	revision	of	ICH	Q9,	in	order	to	
provide	 additional	 guidance	 and	 training	 materials	 in	 certain	 areas	 relating	 to	 the	
application	 of	 QRM	 –	 and	 the	 concept	 of	 formality	 in	 QRM	was	 one	 of	 those	 areas.	 	 In	









the	 level	 of	 risk.	 	What	 formality	 in	QRM	means	 at	 a	 practical	 level	 is	 currently	 not	well	
understood,	and	this	has	probably	led	to	certain	negative	consequences	–	a	lack	of	scientific	
rigour	being	applied	during	some	complex	risk	assessments,	to	the	overuse	of	very	resource	
intensive	 and	 highly	 formalized	 risk	 assessment	 activities	 to	 address	 relatively	 straight	
forward	GMP	problems.			
	
While	 ICH	Q9	does	not	provide	examples	of	what	 formal	 versus	 informal	QRM	mean,	 the	
work	presented	 in	this	paper	shows	that	there	 is	considerable	 interest	 in	the	 industry	and	
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like.	 	 That	 working	 group	 continued	 its	 work	 intermittently	 until	 2020,	 and	 its	 primary	





–	Formal	versus	 Informal;	 rather,	 it	 is	probably	best	considered	along	a	spectrum,	ranging	
from	 high	 levels	 of	 formality	 to	 lower	 levels	 of	 formality.	 	 The	 suggested	 definitions	 for	
formality	in	QRM	presented	in	this	paper	reflect	this	thinking,	and	in	a	follow-up	paper,	they	
will	 be	 further	 explored	 via	 a	 number	 of	 industry/regulator	 case	 studies.	 	 These	 will	
demonstrate	 the	practical	 application	of	 the	 suggested	definitions	presented	here,	 in	 real	
life	GMP	situations.	
		
There	 are	 several	 anticipated	 benefits	 to	 this	 work.	 	 Additional	 clarity	 on	 the	 concept	 of	
formality	in	QRM	may	help	not	only	ensure	that	the	extent	of	scientific	and	methodological	
rigour	applied	during	QRM	is	commensurate	with	the	level	of	risk,	it	may	also	lead	to	resources	for	
QRM	being	used	more	efficiently	–	where	 lower	 risk	 issues	are	dealt	with	more	efficiently	via	 less	
formal	means,	 freeing	 up	 resources	 for	managing	 higher	 risk	 issues	 and	more	 complex	 problems,	
which	 usually	 require	 increased	 levels	 of	 rigour	 and	 effort.	 	 It	 is	 considered	 that	 a	 greater	
understanding	of	formality	in	QRM	has	the	potential	to	lead	to	more	appropriate	and	beneficial	uses	
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on	 pages	 5	 and	 6.	 	 It	 was	 evident	 from	 the	 discussions	 that	 there	 was	 a	 significant	 amount	 of	
uncertainty	about	what	constituted	formality	in	the	context	of	QRM.	There	was	also	a	lack	of	clarity	
on	what	 tools,	 if	 any,	 should	 be	 considered	 to	 be	 less	 formal	when	 compared	 to	 other	 tools	 and	




In	order	 to	 focus	 the	discussions	on	real-life	GMP	 issues,	 there	was	a	discussion	about	 the	kind	of	









QRM	 formality	 should	 be	 applied	 to	 the	 above	 two	 situations.	 	 Overall,	 the	 outcome	 was	




During	 the	workshop,	 an	 attempt	was	made	 to	 develop	 a	 set	 of	 keywords	 that	 could	 be	 used	 to	
























facilitator.	 	 Informal	 QRM,	 on	 the	 other	 hand,	 was	 described	 by	 the	 following	 words	 and	 terms:	






It	 was	 also	 noted	 that,	 during	 the	 workshop,	 the	 attendees	 generally	 agreed	 that	 each	 of	 the	
elements	 of	 the	QRM	process	 as	 per	 ICH	Q9	 (Risk	Assessment,	 Risk	 control,	 Risk	 Review	and	Risk	
Communication)	 should	 be	 regarded	 as	 representing	 formal	 QRM.	 	 The	 attendees	 indicated	 that	
formal	QRM	required	a	 “full	 loop”	approach	 to	 those	elements	 -	meaning	 that	each	of	 those	 four	
elements	should	be	present	and	applied	if	a	QRM	activity	can	be	regarded	as	being	formal	in	nature.		
When	 discussing	 informal	 approaches,	 the	 general	 view	 was	 that	 the	 same	 four	 QRM	 process	
elements	 could	 also	 apply,	 but	 with	 less	 formality.	 	 Again,	 this	 indicated	 the	 need	 for	 a	 better	
understanding	of	the	concept	of	formality	in	QRM,	especially	what	it	might	mean	in	practical	terms.			
	
The	 discussion	 seemed	 to	 suggest	 that,	 just	 like	 with	 formal	 QRM,	 each	 of	 the	 above	 four	 QRM	








indicates	 that,	 when	 there	 are	 clear	 rules	 in	 place	 for	 decision	 making,	 no	 risk	 management	 is	
required	 and	 the	 relevant	 rules	 should	 be	 applied,	 without	 any	 flexibility.	 	 A	 GMP	 example	 here	
might	be	when	a	Qualified	Person	 (QP)	 in	a	manufacturing	plant	 in	 the	EU	 is	deciding	whether	 to	
certify	 a	batch	 for	 release	or	not.	 If	 the	batch	was	out-of-specification	 for	one	attribute	when	QC	












In	 cases	where	 these	 three	 questions	 can	 be	 answered,	 the	 flowchart	 indicates	 that	 informal	 risk	
management	 can	 be	 applied.	 	 And	 according	 to	 the	 flowchart,	 this	 involves	 initiating	 a	 risk	
assessment,	 running	 risk	 control	 measures	 and	 documenting	 the	 results,	 decisions	 and	 actions.		
When	the	above	three	questions	cannot	be	answered,	formal	risk	management	should	be	applied.		
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what	constitutes	 formal	versus	 informal	 risk	management.	 It	 implied	 that	 risk	assessment	and	 risk	
control	were	to	be	performed	when	informal	risk	management	was	required.	However,	a	team	and	a	
risk	management	tool	were	required	during	formal	risk	management,	where	the	QRM	process	was	






It	 was	 also	 considered	 that	 the	 flowchart	 was	 unclear	 as	 to	 where	 risk	 review	 and	 risk	
communication	might	be	applied.	It	made	no	direct	reference	to	those	two	elements	of	QRM	as	per	
ICH	Q9,	unless	the	wording	“Carry	out	the	risk	management	process”	in	the	formal	risk	management	













it	 in	 terms	of	 rigour.	 The	 idea	was	 that	 in	 less	 formal	 approaches	 to	QRM,	 less	 rigour	 is	 generally	
applied	to	the	elements	that	make	up	the	QRM	process	as	per	ICH	Q9	(Risk	Assessment,	Risk	control,	































cause	 analysis	 tools	 and,	 while	 they	 are	 not	 the	 same,	 a	 strong	 approach	 to	 root	 cause	 analysis	
supports	risk	assessment	activities	and	should	be	encouraged.	
	
In	 relation	 to	 informal	QRM,	 it	was	 observed	 during	 the	workshop	 that	 this	was	more	 difficult	 to	
characterise.		It	was	suggested	that	informal	QRM	was	more	event-focused	than	systems-focussed,	
and	 that	 it	 involved	more	 stand-alone	 risk	 assessments	 than	 complete	QRM	 reports.	 	 It	 was	 also	
suggested	that	expressing	formality	in	terms	of	the	degree	of	rigour	that	is	applied	when	assessing	
and	managing	risks	may	be	a	useful	way	of	differentiating	between	formal	and	informal	QRM.		It	was	
generally	agreed	that	 the	 level	of	 rigour	 that	 is	applied	can	also	differ	based	on	the	degree	of	 risk	
that	is	considered	to	be	present.	
	













workshops	 was	 that	 it	 was	 not	 superior.	 	 This	 was	 an	 interesting	 finding,	 and	 it	 was	 somewhat	
unexpected.	 	 (During	 the	 discussions,	 some	 participants	 expressed	 the	 view	 that	 formal	 risk	
assessments	sometimes	end	up	being	only	‘tick	box’	exercises,	and	of	little	value.)		
	
The	 second	workshop	ended	with	 an	 agreement	 that	 the	 topic	 of	 formality	 in	QRM	was	of	 direct	
relevance	and	 interest	to	medicines	manufacturers,	and	that	clear	regulatory	guidance	 in	this	area	
was	needed.		As	at	the	first	workshop,	the	participants	agreed	that	the	topic	merited	further	study	
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